全文获取类型
收费全文 | 12613篇 |
免费 | 882篇 |
国内免费 | 146篇 |
专业分类
耳鼻咽喉 | 68篇 |
儿科学 | 1篇 |
妇产科学 | 43篇 |
基础医学 | 522篇 |
口腔科学 | 95篇 |
临床医学 | 1720篇 |
内科学 | 2166篇 |
皮肤病学 | 47篇 |
神经病学 | 470篇 |
特种医学 | 210篇 |
外科学 | 1281篇 |
综合类 | 2543篇 |
预防医学 | 1802篇 |
眼科学 | 17篇 |
药学 | 1549篇 |
21篇 | |
中国医学 | 337篇 |
肿瘤学 | 749篇 |
出版年
2024年 | 12篇 |
2023年 | 193篇 |
2022年 | 378篇 |
2021年 | 614篇 |
2020年 | 534篇 |
2019年 | 462篇 |
2018年 | 558篇 |
2017年 | 493篇 |
2016年 | 611篇 |
2015年 | 594篇 |
2014年 | 1462篇 |
2013年 | 1252篇 |
2012年 | 1164篇 |
2011年 | 1105篇 |
2010年 | 785篇 |
2009年 | 567篇 |
2008年 | 483篇 |
2007年 | 408篇 |
2006年 | 318篇 |
2005年 | 302篇 |
2004年 | 233篇 |
2003年 | 182篇 |
2002年 | 157篇 |
2001年 | 136篇 |
2000年 | 120篇 |
1999年 | 81篇 |
1998年 | 77篇 |
1997年 | 52篇 |
1996年 | 45篇 |
1995年 | 37篇 |
1994年 | 44篇 |
1993年 | 40篇 |
1992年 | 25篇 |
1991年 | 27篇 |
1990年 | 25篇 |
1989年 | 11篇 |
1988年 | 13篇 |
1987年 | 12篇 |
1986年 | 7篇 |
1985年 | 8篇 |
1984年 | 5篇 |
1983年 | 2篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1977年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Research in social & administrative pharmacy》2022,18(8):3284-3289
BackgroundAdverse drug reactions (ADRs) and adverse drug events (ADEs) in older people contribute to a significant proportion of hospital admissions and are common following discharge. Effective interventions are therefore required to combat the growing burden of preventable ADRs. The Prediction of Hospitalisation due to Adverse Drug Reactions in Elderly Community Dwelling Patients (PADR-EC) score is a validated risk score developed to assess the risk of ADRs in people aged 65 years and older and has the potential to be utilised as part of an intervention to reduce ADRs.ObjectivesThis trial was designed to investigate the effectiveness of an intervention to reduce ADR incidence in older people and to obtain further information about ADRs and ADEs in the 12–24 months following hospital discharge.MethodsThe study is an open-label randomised-controlled trial to be conducted at the Royal Hobart Hospital, a 500-bed public hospital in Tasmania, Australia. Community-dwelling patients aged 65 years and older with an unplanned overnight admission to a general medical ward will be recruited. Following admission, the PADR-EC ADR score will be calculated by a research pharmacist, with the risk communicated to clinicians and discussed with participants. Following discharge, nominated general practitioners and community pharmacists will receive the risk score and related medication management advice to guide their ongoing care of the patient. Follow-up with participants will occur at 3 and 12 and 18 and 24 months to identify ADRs and ADEs. The primary outcome is moderate-severe ADRs at 12 months post-discharge, and will be analysed using the cumulative incidence proportion, survival analysis and Poisson regression.SummaryIt is hypothesised that the trial will reduce ADRs and ADEs in the intervention population. The study will also provide valuable data on post-discharge ADRs and ADEs up to 24 months post-discharge. 相似文献
2.
3.
4.
5.
ObjectiveTo investigate the feasibility of transnasal heated humidified high flow nasal cannula oxygen therapy (HFNC) in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with respiratory failure in elderly patients. MethodsA total of 176 elderly patients with AECOPD complicated with respiratory failure who were hospitalized at Peking University Shougang Hospital from December 2016 to January 2022 were enrolled, including 82 patients in an HFNC group and 94 patients in an NPPV group. After treatment, pulse oxygen saturation (SPO2), arterial partial pressure of carbon dioxide (PaCO2), oxygenation index (OI), respiratory rate (RR), heart rate (HR), mean arterial pressure (MAP), comfort score, discharge rate, rate of endotracheal intubation, rate of transfer to intensive care unit (ICU), and mortality were compared between the two groups. The independent sample t-test was used for comparison between the two groups. Statistical data are expressed in percentage or number of cases and the χ2 test was used for their comparisons. ResultsThe SPO2 values at 30 min, 1 h, and 6 h were significantly higher in the HFNC group than in the NPPV group (t=-2.049,-2.618, and -3.314, P=0.043, 0.010, and 0.001, respectively). SPO2 before discharge was significantly lower than that of the NPPV group (t=2.162, P=0.033), but OI at each time point and before discharge had no statistical significance (P>0.05). MAP at 6 h was significantly higher in the HFNC group than in the NPPV group (t=-2.209, P=0.029), but within the normal range. HRs at 2 h and 3 h in the HFNC group were significantly higher than those of the NPPV group (t=-2.199 and -2.336, P=0.030 and 0.021, respectively). There were no significant differences in RR, HR, or MAP between the two groups at other time points and before discharge (P>0.05). There was no significant difference in PaCO2 between the two groups (P>0.05). Comfort score in the HFNC group was significantly higher than that of the NPPV group (t=-46.807, P<0.001). There were no significant differences in discharge rate, ICU transfer rate, endotracheal intubation rate, and mortality between the two groups (P>0.05). ConclusionHFNC is as effective as NPPV in treating elderly patients with AECOPD complicated with type Ⅰ or mild type Ⅱ respiratory failure, and HFNC is more comfortable than NPPV. 相似文献
6.
《Clinical breast cancer》2020,20(5):377-381
BackgroundBreast cancer screening has been shown to reduce breast cancer-associated mortality. However, screening is limited to the targeted age group of 45 to 69 years in New Zealand despite the recognized increased risk with age. This study aims to compare the outcomes of women aged over 70 years with screen-detected and clinically detected cancers.Patients and MethodsA retrospective review was performed of prospectively collected data from June 2000 to May 2013 by the Auckland Breast Cancer Register. Demographic and tumor characteristics of women with invasive cancer and ductal carcinoma in situ diagnosis aged 70 years and over were compared between those screened and clinically detected. Five-year disease-free and overall survival outcomes were reviewed.ResultsA total of 2128 women aged 70 years and over were diagnosed with breast cancer (median, 77 years; interquartile range [IQR], 74-84 years). Of these, 416 (19.5%) were diagnosed through mammography screening, with a median age of 74 years (IQR, 71-77 years) compared with 79 years (IQR, 74-85 years) for those with clinical detected cancer diagnosis. Screen-detected cancers accounted for a significantly higher proportion of diagnoses in those aged 70 to 74 years compared with older patients (P < .001). Screen-detected cancers were of lower T and N stages. Disease-specific survival was significantly longer in screen-detected cancers versus other cancers (5-year survival, 93.7% vs. 81.9%; P < .001), as was overall survival (5-year survival, 84.7% vs. 57.4%; P < .001).ConclusionScreening in those aged 70 years and over continues to identify breast cancer at early stages and with improved survival. Although aware of the potential for lead-time bias and the healthy volunteer effect, there should still be consideration to extend breast cancer screening to patients aged to up 74 years after appropriate assessment of comorbidities and functional status. 相似文献
7.
Ioana A Campean 《Expert opinion on pharmacotherapy》2020,21(10):1193-1200
ABSTRACT
Introduction
Despite an increasingly older pulmonary hypertension (PH) population, data on PH treatments in these patients are limited because there exist no clinical studies dedicated to geriatric groups. Furthermore, elderly patients with comorbidities have been systematically excluded from clinical trials, limiting the evidence base for drugs approved for pulmonary arterial hypertension (PAH). 相似文献8.
Background
Though the optimal treatment regimen in older patients with glioblastoma multiforme (GBM) remains to be established, multiple randomized studies have supported the use of hypofractionated (1–3?weeks) versus traditional regimens (6?weeks). Here we examine hypofractionated regimen practice patterns among older patients with GBM.Methods
We used the National Cancer Database and included individuals aged ≥65?years with GBM diagnosed from 2005 to 2014 undergoing biopsy/resection followed by chemotherapy and radiation initiated ≤8-weeks of diagnosis. We defined traditional fractionation as ≤200?cGy and hypofractionation as >200?cGy. We compared patient characteristics using a chi-squared test and multivariable logistic regression. We compared 90-day mortality rates following initiation of radiation using the Wald statistic in propensity score matched cohorts.Results
The final cohort included 14,931 individuals with 1524 undergoing hypofractionated treatment. From 2005 to 2014 hypofractionated utilization rates were 7%, 9%, 13%, and 18% among those 65–69, 70–74, 75–79, and ≥80?years of age, respectively. Patients treated at an academic/research center had a >60% increased odds (OR, 1.61; 95% CI, 1.43–1.81) of undergoing hypofractionated regimens versus a community center. Ninety-day mortality rates were high in both groups (hypofractionated: 32%; traditional: 24%; p?<?.001).Conclusions
The majority of older GBM patients do not undergo hypofractionated radiation. High 90-day mortality in both groups suggests that hypofractionation may improve the survival-to-treatment time ratio and positively impact patient quality of life. Hypofractionated radiation regimens for GBM should be discussed with older patients and considered for inclusion in efforts to improve the quality and value of cancer care. 相似文献9.
10.
《中国现代医生》2020,58(34):30-34+39
目的 通过探讨肠道非急性感染期反复粪便培养金黄色葡萄球菌阳性的老年患者口服万古霉素的效果,为此类患者提供一种潜在的治疗方案。方法 前瞻性分析吉林大学第一医院干部病房2015 年9 月~2018 年12 月收治的186 例肠道非急性感染期反复粪便培养金黄色葡萄球菌阳性的老年患者。根据是否口服万古霉素治疗分为万古组和对照组。收集两组患者的一般临床资料,比较两组患者试验前后万古霉素血药浓度、血常规、降钙素原(PCT)、C 反应蛋白(CRP),试验期间粪便培养结果、体温、抗生素使用情况。结果 试验治疗期间,万古组便培养转阴率高于对照组,差异有统计学意义(P<0.05);万古组发热率(29.75%)低于对照组的34.77%,差异有高度统计学意义(P<0.01);万古组抗生素使用率(4.49%)低于对照组的19.23%,差异有高度统计学意义(P<0.01)。试验前两组白细胞、中性粒细胞计数、中性粒细胞比例、PCT、CRP 比较,差异无统计学意义(P>0.05);试验后万古组白细胞、中性粒细胞计数、中性粒细胞比例、CRP 低于对照组,差异有高度统计学意义(P<0.01)。试验后万古组白细胞、中性粒细胞计数、中性粒细胞比例、CRP 低于试验前,差异有高度统计学意义(P<0.01)。结论 口服万古霉素可能提高肠道非急性感染期反复粪便培养金黄色葡萄球菌阳性的老年患者粪便转阴率,减少发热及抗生素的应用,降低炎症细胞水平,可能是此类患者一种潜在的临床治疗方案。 相似文献